Prognostic impact of admission high-sensitivity C-reactive protein in acute myocardial infarction patients with and without diabetes mellitus

[1]  M. De Metrio,et al.  Diabetes Mellitus and Acute Myocardial Infarction: Impact on Short and Long-Term Mortality. , 2020, Advances in experimental medicine and biology.

[2]  2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2020 , 2019, Diabetes Care.

[3]  R. Ceriani,et al.  High-Sensitivity C-Reactive Protein and Acute Kidney Injury in Patients with Acute Myocardial Infarction: A Prospective Observational Study , 2019, Journal of clinical medicine.

[4]  A. von Eckardstein,et al.  Diabetes and baseline glucose are associated with inflammation, left ventricular function and short- and long-term outcome in acute coronary syndromes: role of the novel biomarker Cyr 61 , 2019, Cardiovascular diabetology.

[5]  A. Gabrielsen,et al.  High-sensitivity C-reactive protein and the risk of chronic kidney disease progression or acute kidney injury in post-myocardial infarction patients. , 2019, American heart journal.

[6]  M. Jeong,et al.  Time-dependent prognostic effect of high sensitivity C-reactive protein with statin therapy in acute myocardial infarction. , 2019, Journal of cardiology.

[7]  F. Veglia,et al.  Reduced Cardio-Renal Function Accounts for Most of the In-Hospital Morbidity and Mortality Risk Among Patients With Type 2 Diabetes Undergoing Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction , 2019, Diabetes Care.

[8]  C. Garlichs,et al.  Selective C‐Reactive Protein‐Apheresis in Patients , 2019, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[9]  Yuehua Wu,et al.  Baseline plasma fibrinogen is associated with haemoglobin A1c and 2-year major adverse cardiovascular events following percutaneous coronary intervention in patients with acute coronary syndrome: a single-centre, prospective cohort study , 2019, Cardiovascular Diabetology.

[10]  M. Shao,et al.  Association of Initial and Serial C-Reactive Protein Levels With Adverse Cardiovascular Events and Death After Acute Coronary Syndrome: A Secondary Analysis of the VISTA-16 Trial , 2019, JAMA cardiology.

[11]  Volkmar Falk,et al.  2018 ESC/EACTS Guidelines on myocardial revascularization. , 2018, European heart journal.

[12]  I. Tanboğa,et al.  The C-Reactive Protein to Albumin Ratio Predicts Acute Kidney Injury in Patients With ST-segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. , 2019, Heart, lung & circulation.

[13]  K. Walley.  Sepsis-induced myocardial dysfunction , 2018, Current opinion in critical care.

[14]  D. Lim,et al.  Association between epicardial adipose tissue, high-sensitivity C-reactive protein and myocardial dysfunction in middle-aged men with suspected metabolic syndrome , 2018, Cardiovascular Diabetology.

[15]  J. Gu,et al.  Impact of C-reactive protein on long-term mortality in acute myocardial infarction patients with diabetes and those without. , 2018, Clinica chimica acta; international journal of clinical chemistry.

[16]  F. Veglia,et al.  Prognostic Value of the Acute-to-Chronic Glycemic Ratio at Admission in Acute Myocardial Infarction: A Prospective Study , 2018, Diabetes Care.

[17]  P. Libby,et al.  Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial , 2017, The Lancet.

[18]  P. Libby,et al.  Acute Coronary Syndromes: The Way Forward From Mechanisms to Precision Treatment , 2017, Circulation.

[19]  P. Libby,et al.  Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease , 2017, The New England journal of medicine.

[20]  E. Diamantis,et al.  The Anti-Inflammatory Effects of Statins on Coronary Artery Disease: An Updated Review of the Literature , 2017, Current cardiology reviews.

[21]  A. Reiner,et al.  Oxidative stress, inflammation, endothelial dysfunction and incidence of type 2 diabetes , 2016, Cardiovascular Diabetology.

[22]  J. Danesh,et al.  Association of Multiple Biomarkers of Iron Metabolism and Type 2 Diabetes: The EPIC-InterAct Study , 2016, Diabetes Care.

[23]  Anja,et al.  The Association of Multiple Biomarkers of Iron Metabolism and Type 2 Diabetes - the EPIC-InterAct Study Short running title: Iron Metabolism and Type 2 Diabetes Incidence , 2016 .

[24]  R. Kunze,et al.  Selective apheresis of C‐reactive protein: A new therapeutic option in myocardial infarction? , 2015, Journal of clinical apheresis.

[25]  Iciar Martín-Timón,et al.  Type 2 diabetes and cardiovascular disease: Have all risk factors the same strength? , 2014, World journal of diabetes.

[26]  Michael J Blaha,et al.  High-sensitivity C-reactive protein and cardiovascular disease: a resolute belief or an elusive link? , 2013, Journal of the American College of Cardiology.

[27]  R. Hotchkiss,et al.  Mechanisms of cardiac and renal dysfunction in patients dying of sepsis. , 2013, American journal of respiratory and critical care medicine.

[28]  M. Singer,et al.  The heart in sepsis: from basic mechanisms to clinical management. , 2013, Current vascular pharmacology.

[29]  John Pernow,et al.  Identification and Predictive Value of Interleukin-6+ Interleukin-10+ and Interleukin-6− Interleukin-10+ Cytokine Patterns in ST-Elevation Acute Myocardial Infarction , 2012, Circulation research.

[30]  G. Stone,et al.  Diabetes mellitus, myocardial reperfusion, and outcome in patients with acute ST-elevation myocardial infarction treated with primary angioplasty (from HORIZONS AMI). , 2012, The American journal of cardiology.

[31]  Helmut Baumgartner,et al.  ESC / EACTS Guidelines on myocardial revascularization , 2014 .

[32]  F. Crea,et al.  High-sensitivity C-reactive protein is within normal levels at the very onset of first ST-segment elevation acute myocardial infarction in 41% of cases: a multiethnic case-control study. , 2011, Journal of the American College of Cardiology.

[33]  Volkmar Falk,et al.  Guidelines on Myocardial Revascularization the Task Force on Myocardial Revascularization of the European Society of Cardiology (esc) and the European Association for Cardio-thoracic Surgery (eacts) Developed with the Special Contribution of the European Association for Percutaneous Cardiovascular I , 2022 .

[34]  C. Meisinger,et al.  Admission C-reactive protein and short- as well as long-term mortality in diabetic versus non-diabetic patients with incident myocardial infarction , 2010, Clinical Research in Cardiology.

[35]  A. M. Leone,et al.  Baseline systemic inflammatory status and no-reflow phenomenon after percutaneous coronary angioplasty for acute myocardial infarction. , 2007, International journal of cardiology.

[36]  R. Califf,et al.  A Tale of Two Trials: A Comparison of the Post–Acute Coronary Syndrome Lipid-Lowering Trials A to Z and PROVE IT–TIMI 22 , 2006, Circulation.

[37]  W. Markiewicz,et al.  Early inflammation and risk of long-term development of heart failure and mortality in survivors of acute myocardial infarction predictive role of C-reactive protein. , 2006, Journal of the American College of Cardiology.

[38]  K. Dickstein,et al.  Prognostic risk of atrial fibrillation in acute myocardial infarction complicated by left ventricular dysfunction: the OPTIMAAL experience. , 2005, European heart journal.

[39]  K. Dickstein,et al.  Prognostic risk of atrial fibrillation in acute myocardial infarction complicated by left ventricular dysfunction: the OPTIMAAL experience. , 2005, European heart journal.

[40]  Jing Ma,et al.  Inflammatory markers and the risk of coronary heart disease in men and women. , 2004, The New England journal of medicine.

[41]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[42]  P. Ridker,et al.  Do atherosclerosis and type 2 diabetes share a common inflammatory basis? , 2002, European heart journal.

[43]  P. Libby,et al.  Inflammation and Atherosclerosis , 2002, Circulation.

[44]  B. Horne,et al.  Usefulness of high-sensitivity C-reactive protein in predicting long-term risk of death or acute myocardial infarction in patients with unstable or stable angina pectoris or acute myocardial infarction. , 2002, The American journal of cardiology.

[45]  S. Yusuf,et al.  Impact of Diabetes on Long-Term Prognosis in Patients With Unstable Angina and Non–Q-Wave Myocardial Infarction: Results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry , 2000, Circulation.

[46]  M. Pepys,et al.  Metabolic and scintigraphic studies of radioiodinated human C-reactive protein in health and disease. , 1993, The Journal of clinical investigation.

[47]  BOULIN,et al.  Classification and Diagnosis of Diabetes. , 2022, Primary care.